Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection
- PMID: 22892134
- PMCID: PMC3434083
- DOI: 10.1186/1471-2407-12-264
Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection
Abstract
Background: Palliative surgery followed by postoperative chemotherapy is a challenging approach in the treatment of stage IV gastric cancer yet patients must be carefully selected on the basis of likely clinical benefit.
Methods: The records of 218 patients with histological diagnosis of gastric adenocarcinoma who underwent palliative surgery followed by postoperative chemotherapy were retrospectively reviewed. Twelve potential prognostic variables including tumour DNA index and serum IgG anti- Helicobacter pylori (HP) antibodies were evaluated for their influence on overall survival by multivariate analysis.
Results: The median survival was 13.25 months [95% Confidence Interval (CI) 12.00, 14.50]. Three factors were found to have an independent effect on survival: performance status (PS) [PS 60-70 vs. 90-100 Hazard Ratio (HR) 1.676; CI 1.171-2.398, p = 0.005], liver metastases (HR 1.745; CI 1.318-2.310, p < 0.001), and DNA Index as assessed by Image cytometry (2.2-3.6 vs. >3.6 HR 3.059; CI 2.185-4.283, p < 0.001 and <2.2 vs. >3.6 HR; 4.207 CI 2.751-6.433 <0.001). HP infection had no statistically significant effect on survival by either univariate or multivariate analysis.
Conclusion: Poor pre-treatment PS, the presence of liver metastasis and high DNA Index were identified factors associated with adverse survival outcome in patients with Stage IV gastric cancer treated with palliative gastrectomy and postoperative chemotherapy. HP infection had no influence on survival of these patients.
Figures
Similar articles
-
Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years.Gastric Cancer. 2020 Nov;23(6):1051-1063. doi: 10.1007/s10120-020-01076-2. Epub 2020 May 2. Gastric Cancer. 2020. PMID: 32361784
-
Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer.Cancer Res Treat. 2016 Jul;48(3):1020-9. doi: 10.4143/crt.2015.264. Epub 2015 Nov 17. Cancer Res Treat. 2016. PMID: 26582396 Free PMC article.
-
Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma.Ann Surg Oncol. 2016 Apr;23(4):1225-33. doi: 10.1245/s10434-015-4953-x. Epub 2015 Nov 9. Ann Surg Oncol. 2016. PMID: 26553442
-
[Helicobacter pylori and gastric cancer. The incidence of infection in personal experience].Minerva Chir. 2002 Oct;57(5):649-55. Minerva Chir. 2002. PMID: 12370666 Review. Italian.
-
Liver metastases from gastric carcinoma: A Case report and review of the literature.Curr Probl Cancer. 2017 May-Jun;41(3):222-230. doi: 10.1016/j.currproblcancer.2017.03.003. Epub 2017 Mar 24. Curr Probl Cancer. 2017. PMID: 28625333 Review.
Cited by
-
CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.Med Oncol. 2013 Dec;30(4):726. doi: 10.1007/s12032-013-0726-1. Epub 2013 Sep 12. Med Oncol. 2013. PMID: 24026662
-
Factors Influencing Survival in Stage IV Colorectal Cancer: The Influence of DNA Ploidy.ISRN Gastroenterol. 2013 Jun 4;2013:490578. doi: 10.1155/2013/490578. Print 2013. ISRN Gastroenterol. 2013. PMID: 23840958 Free PMC article.
-
Protective role of Helicobacter pylori infection in prognosis of gastric cancer: evidence from 2,454 patients with gastric cancer.PLoS One. 2013 May 7;8(5):e62440. doi: 10.1371/journal.pone.0062440. Print 2013. PLoS One. 2013. PMID: 23667477 Free PMC article.
-
Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.BMC Cancer. 2022 Feb 8;22(1):155. doi: 10.1186/s12885-022-09222-y. BMC Cancer. 2022. PMID: 35135494 Free PMC article. Review.
-
Effect of Helicobacter pylori infection on outcomes in resected gastric and gastroesophageal junction cancer.J Gastrointest Oncol. 2017 Jun;8(3):583-588. doi: 10.21037/jgo.2017.01.22. J Gastrointest Oncol. 2017. PMID: 28736645 Free PMC article.
References
-
- Fujitani K, Yang HK, Kurokawa Y, do Park J, Tsujinaka T, Park BJ, Fukuda H, Noh SH, Boku N, Bang YJ. et al.Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol. 2008;38(7):504–506. doi: 10.1093/jjco/hyn058. - DOI - PubMed
-
- Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2008;61(2):301–307. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous